Delving into the Latest Updates on Ulinastatin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

UTI, Ulinastatin (JP17), hUTI

+ [12]

Target

Trypsin

Mechanism

Trypsin inhibitors

Therapeutic Areas

Infectious DiseasesDigestive System DisordersOther Diseases

Active Indication

PancreatitisShock, HemorrhagicShock, Septic+ [2]

Inactive Indication

Acute Lung InjuryReperfusion InjuryRespiratory Distress Syndrome, Adult

Originator Organization

Mochida Pharmaceutical Co., Ltd.

Active Organization

Mochida Pharmaceutical Co., Ltd.

Jiangsu Aidea Pharmaceutical Co., Ltd.

Techpool Bio-Pharma Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (16 Apr 1985),

PancreatitisShock, HemorrhagicShock, Septic+ [1]

RegulationOrphan Drug (EU)

Login to view timeline

Gene Sequence

Sequence Code 14926724

Source: *****

Qitong Lu, Zhiyong Liu, Wei He and Xin Chu. Protective effects of ulinastatin on rats with acute lung injury induced by lipopolysaccharide. Bioengineered. 2021 Oct. doi: 10.1080/21655979.2021.1987083.Since publication, significant concerns have been raised about the compliance with ethical policies for human research and the integrity of the data reported in the article.When approached for an explanation, the authors provided some original data but were not able to provide all the necessary supporting information. As verifying the validity of published work is core to the scholarly record's integrity, we are retracting the article. All authors listed in this publication have been informed.We have been informed in our decision-making by our editorial policies and the COPE guidelines. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted.'

31 Dec 2024·Bioengineered

Statement of Retraction: Protective effects of ulinastatin on rats with acute lung injury induced by lipopolysaccharide

01 Dec 2024·International Immunopharmacology

Ulinastatin attenuates renal ischemia–reperfusion injury by inhibiting NLRP3 inflammasome-triggered pyroptosis

Article

Author: Zhang, Hao ; Chen, Dawei ; Wan, Xin ; Zhang, Feng ; Wang, Lei ; Ma, Mengqing ; Huang, Wenjuan ; Cao, Changchun ; Zhang, Yang

Systemic inflammation is involved in developing acute kidney injury (AKI) after cardiac surgery with cardiopulmonary bypass (CPB). Ulinastatin, a urinary trypsin inhibitor (UTI), has various anti-inflammatory effects. Our previous data displayed that UTI administration during CPB played a protective role in reducing the risk of AKI after cardiac surgery; however, its role in AKI pathogenesis remains unknown. In this study, UTI effectively decreased the expression levels of inflammatory factors, including tumor necrosis factor (TNF)-α, interleukin (IL)-6, and interleukin (IL)-18, in patients with CPB. Moreover, the proportion of patients with postoperative AKI decreased significantly. Experimental AKI was induced by 35 min of ischemia, followed by 48 h of reperfusion.The results showed that the preoperative administration of UTI reduced inflammatory cell infiltration and decreased the levels of pro-inflammatory cytokines, including IL-6, IL-18, and TNFα. Meanwhile, UTI inhibited apoptosis, reduced mitochondrial reactive oxygen species production. We further revealed that UTI could inhibit NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome activation by increasing the expression of nuclear factor-κB (IκB) kinase-alpha (IKKα) interacting with apoptosis-associated speck-like protein containing CARD (ASC) to alleviate kidney damage. These findings provide evidence of the renoprotective role of UTI in cardiac surgery-associated (CSA)-AKI, which is associated with the inhibition of NLRP3 inflammasome activation by upregulating IKKα.

100 Deals associated with Ulinastatin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D05183	Ulinastatin	B02AB05	DB12038

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pancreatitis	JP	Mochida Pharmaceutical Co., Ltd.	16 Apr 1985
Shock, Hemorrhagic	JP	Mochida Pharmaceutical Co., Ltd.	16 Apr 1985
Shock, Septic	JP	Mochida Pharmaceutical Co., Ltd.	16 Apr 1985
Shock, Traumatic	JP	Mochida Pharmaceutical Co., Ltd.	16 Apr 1985

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Reperfusion Injury	Phase 2	CN	Jiangsu Aidea Pharmaceutical Co., Ltd.	03 Jul 2019
Respiratory Distress Syndrome, Adult	Phase 2	CN	Techpool Bio-Pharma Co., Ltd.	01 Aug 2016
Acute Lung Injury	Phase 2	CN	Techpool Bio-Pharma Co., Ltd.	18 Aug 2014
Systemic Inflammatory Response Syndrome	Phase 2	CN	Techpool Bio-Pharma Co., Ltd.	18 Aug 2014
Intraoperative Complications	Phase 1	CN	Jiangsu Aidea Pharmaceutical Co., Ltd.	30 Jan 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03387774 (ASCO2024) Manual	Phase 3	Advanced Nasopharyngeal Carcinoma	179	intensity modulated radiation therapy + concurrent chemotherapy + Ulinastatin	hkycilwdmb(fzaajxsvpz) = esmbeptodb nbumwdajyp (labybsdjjo ) View more	Positive	24 May 2024
NCT03387774 (ASCO2024) Manual	Phase 3	Advanced Nasopharyngeal Carcinoma	179	ulinastatinodulated radiation therapy + concurrent chemotherapy	hkycilwdmb(fzaajxsvpz) = olgpsqkogn nbumwdajyp (labybsdjjo ) View more	Positive	24 May 2024
DDW2023	Not Applicable	Post-ERCP Pancreatitis	-	Ulinastatin	aqxwoqvqtn(afmbskgfjy) = fltjvbzzoq vpnzpbquxb (kbyktxxsju )	-	08 May 2023
DDW2023	Not Applicable	Post-ERCP Pancreatitis	-	Ulinastatin	cjccemisbg(imuzvdfvec) = mwniiidepm jcpvljqptk (vfkvptllcy )	-	08 May 2023
DDW2023	Not Applicable	Post-ERCP Pancreatitis	-	Ulinastatin	(zucanrmlrk) = ukhxttnvwd fprmrtpgbf (hqgzlamnnk ) View more	-	08 May 2023
DDW2023	Not Applicable	Post-ERCP Pancreatitis	-	Ulinastatin	sxdksyilqt(jwgpvfakbl) = ccgkvvpqfv futctyjefb (ecvyzucwuo )	-	08 May 2023
ISN WCN2023	Not Applicable	SOFA scores \| d-dimer \| serum procalcitonin levels ... View more	200	Ulinastatin	oxwdhfyznb(jgdhjejana) = aykhcamzxv ymhwlvrhfn (jewulbyhhq ) View more	Positive	01 Mar 2023
NCT01060189 (Pubmed \| J Cardiothorac Surg)	Not Applicable	-	426	Ulinastatin	dztdqkgkih(zvtkhdwqob) = ieavnnhdog ccspvonqcs (fuqthnlzwn )	Positive	14 May 2020
NCT01060189 (Pubmed \| J Cardiothorac Surg)	Not Applicable	-	426	Tranexamic acid	dztdqkgkih(zvtkhdwqob) = biiihxqauo ccspvonqcs (fuqthnlzwn )	Positive	14 May 2020
ERA2016	Not Applicable	Acute Kidney Injury	150	Ulinastatin	(juoelhrfmr) = amndujrrxv wslrtaruyb (xveaggsxtx ) View more	Positive	14 May 2016
ERA2016	Not Applicable	Acute Kidney Injury	150	ULINASTATIN	ckvsduzzay(vqmaafjvrv) = kvgladhtjf njffyzqnrv (kqhftrrzkj )	Positive	14 May 2016
NCT01132521 (Pubmed \| Clin Gastroenterol Hepatol)	Phase 4	Post-ERCP acute pancreatitis	406	Ulinastatin	(mdmqeoifou) = ujxemvdnrj izvopjdgwb (lzzcrtucor )	Positive	01 Apr 2005
NCT01132521 (Pubmed \| Clin Gastroenterol Hepatol)	Phase 4	Post-ERCP acute pancreatitis	406	Placebo	(mdmqeoifou) = qcopqnrqfn izvopjdgwb (lzzcrtucor )	Positive	01 Apr 2005